CSI Market
Sign In | Register

Ultragenyx Pharmaceutical Inc (RARE) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access RARE quarterly Cash Flow →
A period-by-period view of cash flow from Ultragenyx Pharmaceutical Inc to Dec 31 2021 helps clarify how Dec 31 2025's cash position has changed over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-575.00
Depreciation & amortization35.00
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-6.00
Research and Development in Process0.00
Gain (Loss) on Disposition of Intangible Assets0.00
Share-based Compensation0.00
Income (Loss) from Equity Method Investments0.00
Foreign Currency Transaction Gain (Loss), before Tax, Total0.00
Increase Decrease In Right O F Use Assets-
Equity Securities Fv Ni Gain Loss-
Increase Decrease In Right Of Use Assets-
Increase Decrease In Accounts Payable Accrued Liabilities And Other Operating Liabilities24.00
Non Cash Royalty Revenue-112.00
Allocated Share Based Compensation Expense Net Of Capitalized Inventory Cost153.00
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable-31.00
Increase (Decrease) in Accounts Payable0.00
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expenses, Other-10.00
Other Working Capital0.00
Other Noncash Income (Expense)-2.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities58.00
Discontinued operations0.00
Net Cash flow from Operating Activities-466.00
Investing Activities
Capital Expenditures-21.00
Sale of Capital Items0.00
Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities444.00
Payments to Acquire Available-for-sale Securities, Debt-186.00
Payments for Tenant Improvements0.00
Proceeds From Sale Of Equity Investment-
Purchase Of Mutual Funds Related To Nonqualified Deferred Compensation Plan-
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Net of Cash Acquired0.00
Payments to Acquire Equity Method Investments0.00
Sale of businesses0.00
Accounts payable0.00
Payments to Acquire Notes Receivable0.00
Payments for (Proceeds from) Other Investing Activities-1.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities236.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock6.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net392.00
Embedded Derivative No Longer Bifurcated Amount Reclassified To Stockholders Equity-
Proceeds From Issuance Of Common Stock At Market Offering80.00
Proceeds From Issuance Of Common Stock In Connection With License Agreement-
Finance Lease Principal Payments-
Payments For Proceeds From Issuance Of Common Stock Under Equity Plan-
Payments of Ordinary Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities478.00
Effect of exchange rate on cash flow4.00
Discontinued operations0.00
Free Cash Flow-487.00
Total Cash Flow252.00
4 historic quarters locked

Sign in to unlock the full Ultragenyx Pharmaceutical Inc cash flow history.

Sign In Create Free Account

About Ultragenyx Pharmaceutical Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: February 18, 2026
  • Source: rare-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-057329

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License